menu

CME: How to Choose the Right Treatment for COPD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How to Choose the Right Treatment for COPD

How to Choose the Right Treatment for COPD
RestartResume
The availability of various therapeutic options for COPD can make it challenging to identify the most effective one, but not impossible.

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    To help clinicians narrow down which therapeutic option would be best for each individual patient with chronic obstructive pulmonary disease (COPD), pulmonologist and Chief Medical Officer for the COPD Foundation Dr. Byron Thomashow, Chief Science Officer for the COPD Foundation and primary care physician Dr. Barbara Yawn, and COPD patient Ms. Debbie Daro come together to discuss the variety of pharmacologic and non-pharmacologic options available and how we can treat the whole patient—not just the disease.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the COPD Foundation (COPDF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and COPDF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF and COPDF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and COPDF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures
    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    Faculty DisclosuresContent Creators
    The faculty listed below report that they have no relevant financial relationships to disclose:

    • Debra Daro

    The following faculty report that they have relevant financial relationships to disclose:

    • Dr. Barbara Yawn serves on advisory boards for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, and Pfizer, Inc.
    • Dr. Byron Thomashow serves on advisory boards for AstraZeneca and GlaxoSmithKline

    The planners, reviewers, staff and other members of the COPD Foundation who control content have no relevant financial relationships to disclose. 

    DISCLOSURE OF UNLABELED USE
    TFF and COPDF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and COPDF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

  • Target Audience

    This educational initiative is intended for primary care clinicians, pulmonologists, respiratory nurses and therapists, and other healthcare professionals who provide care for patients and families living with COPD.

  • Learning Objectives

    Upon completion of the activity, participants should be able to:

    • Emphasize benefits of pulmonary rehabilitation to patient.
    • Review the single- and fixed-dose dual and triple therapy combination pharmacologic options for the management of COPD and drug delivery considerations
    • Review over and under use data for bronchodilators and ICS
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the COPD Foundation. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION
    Physicians
    The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Nurses
    Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

  • Provider(s)/Educational Partner(s)

       

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/15/19